Abstract
Previous investigations have demonstrated that endogenous inhibitors of nitric oxide synthase (NOS), such as asymmetric dimethylarginine (ADMA), contribute importantly to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in rats treated with low-density lipoprotein (LDL) by reducing ADMA levels. In the present study, we explored further the possible mechanism underlying inhibition of ADMA generation by fenofibrate in cultured human umbilical vein endothelial cells (HUVECs). Endothelial injury was induced in cultured HUVECs by incubation with oxidative LDL (ox-LDL) and the levels of ADMA, lactate dehydrogenase (LDH), NO and tumour necrosis factor-α (TNF-α) in the conditioned medium were measured. Cell viability and the activity of dimethylarginine dimethylaminohydrolase (DDAH) and nuclear factor-κB (NF-κB) in the cultured HUVECs were also determined. Incubation of HUVECs with ox-LDL (100 μg/ml) for 24 h markedly elevated ADMA, LDH and TNF-α in the conditioned medium and significantly increased the activity of NF-κB, concomitantly with a significant decrease in the activity of DDAH and the content of NO. Pretreatment with fenofibrate (3, 10 or 30 μM) significantly inhibited the increases in ADMA, LDH and TNF-α, attenuated the decreased levels of NO and the decreased activity of DDAH and prevented the activation of NF-κB. Similar effects were observed in the presence of pyrrolidine dithiocarbamate (PDTC, 10 μM), an antagonist of NF-κB. The beneficial effects of fenofibrate on cultured endothelial cells were abolished by MK-886, a specific peroxisome proliferator-activated receptor-α (PPARα) antagonist. The present results suggest that fenofibrate inhibits ox-LDL-induced endothelial cell damage by decreasing ADMA and increasing DDAH activity, and the protective effects of fenofibrate on endothelial cells may be related to reduction of NF-κB activity by activation of the PPARα receptor.
Similar content being viewed by others
References
Bessman JD, Gardner FH (1983) Platelet size in thrombocytopenia due to sepsis. Surg Gynecol Obstet 156:177–180
Boger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824–833
Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP (2000a) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36:2287–2295
Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR (2000b) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:1557–1564
Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM (2000c) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99–105
Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, Palinski W, Shah PK, Cercek B, Nilsson J, Regnstrom J (1998) An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 18:884–893
Canty TG, Boyle EM, Farr A, Morgan EN, Verrier ED, Pohlman TH (1999) Oxidant stress induces NF-κB nuclear translocation without degradation of IκBα. Circulation 100:II361–II364
Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP (2000) Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20:1040–1046
Chen BM, Xia LW, Zhao RQ (1997) Determination of NG,NG-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 692:467–471
Collins T, Cybulsky MI (2001) NF-κB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107:255–264
Cybulsky MI, Gimbrone MA (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788–791
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B (1999) Peroxisome proliferator-activated receptor-α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem 274:32048–32054
Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279–284
Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20:2039–2044
Feng Q, Lu X, Jones DL, Shen J, Arnold JM (2001) Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:700–704
Havel RJ, Eder HA, Bragdon JH (1995) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092–3095
Jiang JL, Li NS, Li YJ, Deng HW (2002) Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 135:1175–1182
Jiang DJ, Jiang JL, Tan GS, Du YH, Xu KP, Li YJ (2003) Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn-Schmiedeberg’s Arch Pharmacol 367:600–606
Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ (2004) Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 25:893–901
Kiemer AK, Vollmar AM (1998) Autocrine regulation of inducible nitric oxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem 273:13444–13451
Kurowska EM (2002) Nitric oxide therapies in vascular diseases. Curr Pharm Des 8:155–166
Liang B, McMaster JC, Kroeger EA, Hatch GM, Mymin D, Dembinski T, Arthur G, Shen G, Man RY, Choy PC (2000) The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients. Mol Cell Biochem 207:123–129
Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987–992
Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J (2001) Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial—FAT). Cardiovasc Res 52:290–298
Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125–3131
Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141–1146
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8:679–683
Niemann-Jonsson A, Dimayuga P, Jovinge S, Calara F, Ares MP, Fredrikson GN, Nilsson J (2000) Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-α expression. Arterioscler Thromb Vasc Biol 20:2205–2211
Okopien B, Cwalina L, Haberka M, Kowalski J, Zielinski M, Szwed Z, Kalina Z, Herman ZS (2002) Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia. Pol Merkuriusz Lek 13:465–469
Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R (2003) Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 41:219–222
Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A (2002) PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143–151
Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K (2003) High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18:177–182
Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D’Alecy LG, Rajagopalan S (2003) Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 18:2415–2420
Teppo AM, Maury CP (1987) Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 33:2024–2027
Xiong Y, Li YJ, Yu XJ, Liu GZ, Li NS (1996) Endogenous inhibitors of nitric oxide synthesis and lipid peroxidation in hyperlipidemic rabbits. Acta Pharmacol Sin 17:149–152
Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ (2004) Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn-Schmiedeberg’s Arch Pharmacol 370:79–83
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, TL., Chen, MF., Luo, BL. et al. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-κB activity. Naunyn Schmied Arch Pharmacol 371, 401–407 (2005). https://doi.org/10.1007/s00210-005-1060-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-005-1060-8